The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia ; day:16 ; month:11 ; year:2021 ; pages:1-15
Advances in therapy ; (16.11.2021), 1-15
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01948-8
- URN
-
urn:nbn:de:101:1-2022012620555117556213
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Santini, Valeria
- Lübbert, Michael
- Wierzbowska, Agnieszka
- Ossenkoppele, Gert J.
- SpringerLink (Online service)
Other Objects (12)
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Absence of early platelet increment in healthy mice during decitabine treatment
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Absence of early platelet increment in healthy mice during decitabine treatment
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG